Tubular overexpression of gremlin in transgenic mice aggravates renal damage in diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 6, 2015, Pages F559-F568

  Marchant, Vanessa ^a   Droguett, Alejandra ^a   Valderrama, Graciela ^a   Eugenia Burgos, M ^a   Carpio, Daniel ^a   Kerr, Bredford ^b   Ruiz Ortega, Marta ^c   Egido, Jesús ^d   Mezzano, Sergio ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b CENTRO DE ESTUDIOS CIENTÍFICOS CECS   (Chile)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

Diabetic nephropathy; Gremlin

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA1; CREATININE; GREMLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PODOCIN; PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; GREM1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ELECTRON MICROSCOPY; FIBROSING ALVEOLITIS; GENE OVEREXPRESSION; GENE SILENCING; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; IN VIVO STUDY; INFLAMMATORY CELL; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENETICS; GLOMERULUS; HUMAN; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY TUBULE; METABOLISM; PATHOLOGY; PODOCYTE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY GLOMERULUS; KIDNEY TUBULES; MICE, INBRED C57BL; MICE, TRANSGENIC; NEPHRITIS, INTERSTITIAL; PODOCYTES;

EID: 84941671310     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00023.2015     Document Type: Article

References (51)

1. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17: 2974–2984, 2006.
2. Alpers CE, Hudkins KL. Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens 20: 278–284, 2011.
3. Boers W, Aarrass S, Linthorst C, Pinzani M, Elferink RO, Bosma P. Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem 281: 16289–16295, 2006.
4. Breyer MD, Böttinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27–45, 2005.
5. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, Mcindoe RA, Sharma K, Smithies O, Susztak K, Takahashi N. Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503–2512, 2009.
6. Carvajal G, Droguett a Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Ruiz-Ortega M, Egido J, Mezzano S. Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 40: 734–739, 2008.
7. Cho GW, Shin SM, Namkoong H, Kim HK, Ha SA, Hur SY, Kim TE, Chai YG, Kim JW. The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression. Gene 384: 18–26, 2006.
8. Clee SM, Attie AD. The genetic landscape of type 2 diabetes in mice. Endocr Rev 28: 48–83, 2007.
9. Corsini M, Moroni E, Ravelli C, Andrés G, Grillo E, Ali IH, Brazil DP, Presta M, Mitola S. Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. Arterioscler Thromb Vasc Biol 34: 136–145, 2014.
10. Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, Martin F, O’Meara Y, Schmid H, Henger A, Kretzler M, Droguett A, Mezzano S, Brady HR. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 45: 1034–1039, 2005.
11. Droguett A, Krall P, Burgos ME, Valderrama G, Carpio D, Ardiles L, Rodriguez-Diez R, Kerr B, Walz K, Ruiz-Ortega M, Egido J, Mezzano S. Tubular overexpression of gremlin induces renal damage susceptibility in mice. PLoS One 9: e101879, 2014.
12. Eid AA, Gorin Y, Fagg BM, Maalouf R, Barnes JL, Block K, Abboud HE. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 58: 1201–1211, 2009.
13. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 56: 1455–1467, 1999.
14. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy–beyond the RAS. Nat Rev Nephrol 10: 325–346, 2014.
15. Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti VS, Ichimura T, Humphreys BD, Bonventre JV. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 82: 172–183, 2012.
16. Kim M, Yoon S, Lee S, Ha SA, Kim HK, Kim JW, Chung J. Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. PLoS One 7: e35100, 2012.
17. Koli K, Myllärniemi M, Vuorinen K, Salmenkivi K, Ryynänen MJ, Kinnula VL, Keski-Oja J. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 169: 61–71, 2006.
18. Lappin DW, Hensey C, McMahon R, Godson C, Brady HR. Gremlins, glomeruli and diabetic nephropathy. Curr Opin Nephrol Hypertens 9: 469–472, 2000.
19. Lappin DWP, McMahon R, Murphy M, Brady HR. Gremlin: an example of the re-emergence of developmental programmes in diabetic nephropathy. Nephrol Dial Transplant 17, Suppl 9: 65–67, 2002.
20. Lavoz C, Alique M, Rodrigues-Diez R, Pato J, Keri G, Mezzano S, Egido J, Ruiz-Ortega M. Gremlin regulates renal inflammation via vascular endothelial growth factor receptor 2 pathway. J Pathol 236: 407–420, 2015.
21. Lee PT, Chou KJ, Fang HC. Are tubular cells not only victims but also perpetrators in renal fibrosis? Kidney Int 82: 128–130, 2012.
22. Li G, Li Y, Liu S, Shi Y, Chi Y, Liu G, Shan T. Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/smad dependent signaling pathway. J Cell Biochem 114: 2101–2113, 2013.
23. McKnight AJ, Patterson CC, Pettigrew a K, Savage a D, Kilner J, Murphy M, Sadlier D, Maxwell AP. A GREM1 gene variant associates with diabetic nephropathy. J Am Soc Nephrol 21: 773–781, 2010.
24. McMahon R, Murphy M, Clarkson M, Taal M, Mackenzie HS, Godson C, Martin F, Brady HR. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factorbeta1. J Biol Chem 275: 9901–9904, 2000.
25. Michos O, Panman L, Vintersten K, Beier K, Zeller R, Zuniga A. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 131: 3401–3410, 2004.
26. Mitola S, Ravelli C, Moroni E, Salvi V, Leali D, Ballmer-Hofer K, Zammataro L, Presta M. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 116: 3677–3680, 2010.
27. Myllärniemi M, Lindholm P, Ryynänen MJ, Kliment CR, Salmenkivi K, Keski-Oja J, Kinnula VL, Oury TD, Koli K. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 177: 321–329, 2008.
28. Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82: 292–303, 2012.
29. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15: 1379–1383, 2000.
30. Nerlich A, Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139: 889–899, 1991.
31. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342–348, 1997.
32. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 83: 253–307, 2003.
33. Pichaiwong W, Hudkins KL, Wietecha T, Nguyen TQ, Tachaudomdach C, Li W, Askari B, Kobayashi T, O’Brien KD, Pippin JW, Shankland SJ, Alpers CE. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol 24: 1088–1102, 2013.
34. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54: 2628–2637, 2005.
35. Ritz E, Wolf G. Pathogenesis, clinical manifestations, and natural history of diabetic nephropathy. In: Comprehensive Clinical Nephrology (4th ed.). Maryland Heights, MO: Mosby, 2010, p. 359–376.
36. Rodrigues-Diez R, Lavoz C, Carvajal G, Rayego-Mateos S, Rodrigues Diez RR, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. Nephron Exp Nephrol 122: 62–74, 2012.
37. Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz C, Carvajal G, Droguett A, Garcia-Redondo AB, Rodriguez I, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Gremlin activates the smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. Biomed Res Int 2014: 802-841, 2014.
38. Roxburgh a S, Murphy M, Pollock a C, Brazil DP. Recapitulation of embryological programmes in renal fibrosis–the importance of epithelial cell plasticity and developmental genes. Nephron Physiol 103: 139–148, 2006.
39. Roxburgh SA, Kattla JJ, Curran SP, O’Meara YM, Pollock CA, Goldschmeding R, Godson C, Martin F, Brazil DP. Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 58: 1641–1650, 2009.
40. Sanchez-Niño MD, Benito-Martin A, Ortiz A. New paradigms in cell death in human diabetic nephropathy. Kidney Int 78: 737–744, 2010.
41. Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131–2147, 2006.
42. Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, Peri F, Pessi A, Orsatti L, Talamo F, Castronovo V, Waltregny D, Cotelli F, Ribatti D, Presta M. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 109: 1834–1840, 2007.
43. Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225–233, 2006.
44. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 12: 261–266, 2007.
45. Topol LZ, Bardot B, Zhang Q, Resau J, Huillard E, Marx M, Calothy G, Blair DG. Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin. J Biol Chem 275: 8785–8793, 2000.
46. Topol LZ, Marx M, Laugier D, Bogdanova NN, Boubnov NV, Clausen PA, Calothy G, Blair DG. Identification of drm, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture. Mol Cell Biol 17: 4801–4810, 1997. 46a.US Renal Data System. Atlas of CKD & ESRD. http://www.usrds.org/atlas.aspx.
47. Wada J, Sun L, Kanwar YS. Discovery of genes related to diabetic nephropathy in various animal models by current techniques. Contrib Nephrol 169: 161–174, 2011.
48. Wallner EI, Wada J, Lin S, Pan X, Reddy JK, Chugh SS, Kanwar YS. Renal gene expression in embryonic and newborn diabetic mice. Exp Nephrol 10: 130–138, 2002.
49. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71: 1205–1214, 2007.
50. Zhang Q, Shi Y, Wada J, Malakauskas SM, Liu M, Ren Y, Du C, Duan H, Li Y, Li Y, Zhang Y. In Vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS One 5: e11709, 2010.
51. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 13: 2898–2908, 2002.